» Articles » PMID: 26853689

The Cystathionine-β-synthase Domains on the Guanosine 5''-monophosphate Reductase and Inosine 5'-monophosphate Dehydrogenase Enzymes from Leishmania Regulate Enzymatic Activity in Response to Guanylate and Adenylate Nucleotide Levels

Overview
Journal Mol Microbiol
Date 2016 Feb 9
PMID 26853689
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

The Leishmania guanosine 5'-monophosphate reductase (GMPR) and inosine 5'-monophosphate dehydrogenase (IMPDH) are purine metabolic enzymes that function maintaining the cellular adenylate and guanylate nucleotide. Interestingly, both enzymes contain a cystathionine-β-synthase domain (CBS). To investigate this metabolic regulation, the Leishmania GMPR was cloned and shown to be sufficient to complement the guaC (GMPR), but not the guaB (IMPDH), mutation in Escherichia coli. Kinetic studies confirmed that the Leishmania GMPR catalyzed a strict NADPH-dependent reductive deamination of GMP to produce IMP. Addition of GTP or high levels of GMP induced a marked increase in activity without altering the Km values for the substrates. In contrast, the binding of ATP decreased the GMPR activity and increased the GMP Km value 10-fold. These kinetic changes were correlated with changes in the GMPR quaternary structure, induced by the binding of GMP, GTP, or ATP to the GMPR CBS domain. The capacity of these CBS domains to mediate the catalytic activity of the IMPDH and GMPR provides a regulatory mechanism for balancing the intracellular adenylate and guanylate pools.

Citing Articles

The mycobacterial guaB1 gene encodes a guanosine 5'-monophosphate reductase with a cystathionine-β-synthase domain.

Knejzlik Z, Dolezal M, Herkommerova K, Clarova K, Klima M, Dedola M FEBS J. 2022; 289(18):5571-5598.

PMID: 35338694 PMC: 9790621. DOI: 10.1111/febs.16448.


Repurposing existing drugs: identification of irreversible IMPDH inhibitors by high-throughput screening.

Sarwono A, Mitsuhashi S, Kabir M, Shigetomi K, Okada T, Ohsaka F J Enzyme Inhib Med Chem. 2018; 34(1):171-178.

PMID: 30451014 PMC: 6249553. DOI: 10.1080/14756366.2018.1540474.


GMP reductase and genetic uncoupling of adenylate and guanylate metabolism in Leishmania donovani parasites.

Boitz J, Jardim A, Ullman B Mol Biochem Parasitol. 2016; 208(2):74-83.

PMID: 27343371 PMC: 5010971. DOI: 10.1016/j.molbiopara.2016.06.008.

References
1.
Nimmesgern E, Black J, Futer O, Fulghum J, Chambers S, Brummel C . Biochemical analysis of the modular enzyme inosine 5'-monophosphate dehydrogenase. Protein Expr Purif. 1999; 17(2):282-9. DOI: 10.1006/prep.1999.1136. View

2.
Hedstrom L . IMP dehydrogenase: structure, mechanism, and inhibition. Chem Rev. 2009; 109(7):2903-28. PMC: 2737513. DOI: 10.1021/cr900021w. View

3.
Digits J, Hedstrom L . Drug selectivity is determined by coupling across the NAD+ site of IMP dehydrogenase. Biochemistry. 2000; 39(7):1771-7. DOI: 10.1021/bi992288e. View

4.
De Koning H, Watson C, Sutcliffe L, Jarvis S . Differential regulation of nucleoside and nucleobase transporters in Crithidia fasciculata and Trypanosoma brucei brucei. Mol Biochem Parasitol. 2000; 106(1):93-107. DOI: 10.1016/s0166-6851(99)00203-0. View

5.
Jardim A, Liu W, Zheleznova E, Ullman B . Peroxisomal targeting signal-1 receptor protein PEX5 from Leishmania donovani. Molecular, biochemical, and immunocytochemical characterization. J Biol Chem. 2000; 275(18):13637-44. DOI: 10.1074/jbc.275.18.13637. View